Erasca to Present at Upcoming Investor Conferences in September
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in September 2024 and will also participate in one-on-one investor meetings.
22nd Annual Morgan Stanley Global Healthcare Conference
Location: New York Marriott Marquis, New York, NY
Format: Fireside Chat
Date and Time: Thursday, September 5, 12:20 – 12:55 pm Eastern Time
2024 Cantor Global Healthcare Conference
Location: InterContinental Barclay, New York, NY
Format: Fireside Chat
Date and Time: Wednesday, September 18, 3:40 – 4:10 pm Eastern Time
A live audio webcast of the events will be available online at . An archived replay of the events will be available for 30 days following the webcast at .
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
Source: Erasca, Inc.
